
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, …